Darzalex Faspro Injection
Product Images NDC 57894-503

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Darzalex Faspro (NDC 57894-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (15 mL Vial Box)

This is a chart showing the proportion of patients surviving without progression in a clinical trial comparing two treatments (D-Pd vs. Pd). Additionally, it includes the number of patients at risk, median progression-free survival in months, and hazard ratio for each treatment. The numbers represent the amount of time in months.*

FDA Label Image

Darzalex 02

DARZALEX Faspro is an injectable medication containing 1,800mg of daratumumab and 30,000 units of hyaluronidase per 15 mL solution. Each single-dose vial contains inactive ingredients such as histidine hydrochloride, L-methionine, sorbitol, and Water for injection. The medication is administered subcutaneously over 3-5 minutes and is refrigerated at 2°C to 8°C to protect from light. The unused portion of the single-dose vial needs to be discarded.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.